Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the pyrido[2,3-d]pyrimidines class. It features a substituted pyridopyrimidine core with two amino groups at positions 2 and 4 and an N-methyl-N-(3',4',5'-trimethoxybenzyl)amino group at position 6. The compound has been cataloged in chemical and drug databases as an experimental molecule but does not have any approved medical indications or known clinical development programs. Its mechanism of action is not described in public sources; however, related pyridopyrimidine derivatives are often investigated for their potential as enzyme inhibitors or antimetabolites in cancer or antimicrobial research. No evidence suggests this specific compound has reached clinical trials or regulatory approval stages[1][2][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,4-diamino-6-[n-(3',4',5'-trimethoxybenzyl)-n-methylamino]pyrido[2,3-d]pyrimidine.